[HTML][HTML] The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center …
S Tamada, T Iguchi, S Yasuda, M Kato, T Yamasaki… - Oncotarget, 2018 - ncbi.nlm.nih.gov
The difference in the survival rate of patients with metastatic renal cell carcinoma in the
intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria - PMC Back to …
intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria - PMC Back to …
[HTML][HTML] Impact of the discordance between scales of memorial sloan-kettering cancer center and international metastatic renal cell carcinoma database Consortium in …
HJ Grimaldo-Roque… - World Journal of …, 2022 - ncbi.nlm.nih.gov
Background In Mexico, about 30% of renal cancer patients are diagnosed in a metastatic
state. Despite the recent advances in the treatment of cancer, metastatic renal cancer is still …
state. Despite the recent advances in the treatment of cancer, metastatic renal cancer is still …
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database …
Background A novel prognostic model was recommended for patients with metastatic RCC
(mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to …
(mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to …
[PDF][PDF] Prognostic importance of metastatic site in intermediate-risk group metastatic renal cell cancer treated with tyrosine kinase inhibitors
C Karacin, I Bilgetekin, FB Basal, OB Oksuzoglu - Lung, 2020 - researchgate.net
Ob ective: o determine the prognostic importance of the metastatic site in metastatic renal
cell cancer (mRCC) patients in the International Metastatic Renal Cell Carcinoma Database …
cell cancer (mRCC) patients in the International Metastatic Renal Cell Carcinoma Database …
Impact of disagreement between two risk group models on prognosis in patients with metastatic renal-cell carcinoma
K Okita, S Hatakeyama, T Tanaka, Y Ikehata… - Clinical Genitourinary …, 2019 - Elsevier
Purpose To investigate the impact of the risk group disagreement between the Memorial
Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal Cell …
Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal Cell …
[HTML][HTML] Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center risk models in patients …
JK Kim, SH Kim, MK Song, J Joo… - … : Official Journal of …, 2019 - synapse.koreamed.org
Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed …
and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed …
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation
L Derosa, MA Bayar, L Albiges, G Le Teuff, B Escudier - Angiogenesis, 2019 - Springer
Background In patients with metastatic renal cell carcinoma (mRCC), the oncologic benefit
of second-line treatment for high volume tumors or presence of more than five risk factors …
of second-line treatment for high volume tumors or presence of more than five risk factors …
Characterization of patients with poor-risk metastatic renal-cell carcinoma: results from a pooled clinical trials database
Background Poor-risk patients with metastatic renal-cell carcinoma remain poorly
characterized in prospective clinical trials. Therefore, we sought to provide a comprehensive …
characterized in prospective clinical trials. Therefore, we sought to provide a comprehensive …
External validation of the MSKCC and IMDC risk models in patients treated with targeted therapy as a first-line and subsequent second-line treatment: a Japanese …
N Tanaka, R Mizuno, K Ito, S Shirotake… - European urology …, 2016 - Elsevier
Background Two risk models, the Memorial Sloan Kettering Cancer Center (MSKCC) model
and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model …
and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model …
The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).
AL Schmidt, W Xie, CL Gan, C Wells, S Dudani… - 2021 - ascopubs.org
339 Background: The IMDC criteria have been used as a prognostic tool for patients with
mRCC receiving single agent VEGF-targeted drugs, and more recently combination immuno …
mRCC receiving single agent VEGF-targeted drugs, and more recently combination immuno …